Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Original Article

MicroRNA-346 functions as an oncogene in cutaneous squamous cell carcinoma

Authors: Bin Chen, Wenyan Pan, Xiaoxi Lin, Zhenzhen Hu, Yunbo Jin, Hui Chen, Gang Ma, Yajing Qiu, Lei Chang, Chen Hua, Yun Zou, Yang Gao, Hanru Ying, Dongze Lv

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

Cutaneous squamous cell carcinoma (cSCC) is an epidermal keratinocyte-derived skin tumor, which is the second most common skin cancer in the general population. Recently, studies showed that microRNAs (miRNAs) played an important role in the development of cancer. In our study, we showed that the expression of SRCIN1 was lower in cSCC tissues than in the matched normal tissues. Moreover, there was significant inversed correlation between miR-346 and SRCIN1 in cSCC tissues. The luciferase reporter assay data showed that miR-346 can target the SRCIN1 message via the 3′-untranslated region (UTR) of SRCIN1. Overexpression of miR-346 inhibited the messenger RNA (mRNA) and protein expression of SRCIN1 in the A431 cells. In addition, ectopic expression of miR-346 promoted the A431 cell proliferation and migration. Meanwhile, SRCIN1 overexpression inhibited the A431 cell proliferation and migration. Rescue experiment has showed that SRCIN1 overexpression reduced the miR-346-induced A431 cell proliferation and migration. Herein, this study may provide miR-346 as a new therapeutic target for cSCC.
Literature
1.
Wang N, Xu ZW, Wang KH. Systematical analysis of cutaneous squamous cell carcinoma network of microRNAs, transcription factors, and target and host genes. Asian Pac J Cancer Prev: APJCP. 2014;15:10355–61.CrossRefPubMed
2.
Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DS. Epigenetic biomarkers in skin cancer. Cancer Lett. 2014;342:170–7.CrossRefPubMed
3.
Gastaldi C, Bertero T, Xu N, Bourget-Ponzio I, Lebrigand K, Fourre S, et al. miR-193b/365a cluster controls progression of epidermal squamous cell carcinoma. Carcinogenesis. 2014;35:1110–20.CrossRefPubMed
4.
Bruegger C, Kempf W, Spoerri I, Arnold AW, Itin PH, Burger B. MicroRNA expression differs in cutaneous squamous cell carcinomas and healthy skin of immunocompetent individuals. Exp Dermatol. 2013;22:426–8.CrossRefPubMed
5.
Zhou M, Zhou L, Zheng L, Guo L, Wang Y, Liu H, et al. miR-365 promotes cutaneous squamous cell carcinoma (CSCC) through targeting nuclear factor I/B (NFIB). PLoS ONE. 2014;9, e100620.CrossRefPubMedPubMedCentral
6.
Ning MS, Andl T. Custodians of the transcriptome: how microRNAs guard stemness in squamous epithelia. Stem Cells. 2014;33(4):1047–54.CrossRef
7.
Sand M, Skrygan M, Georgas D, Sand D, Hahn SA, Gambichler T, et al. Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma. J Dermatol Sci. 2012;68:119–26.CrossRefPubMed
8.
9.
Yamane K, Jinnin M, Etoh T, Kobayashi Y, Shimozono N, Fukushima S, et al. Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. J Mol Med (Berl). 2013;91:69–81.CrossRef
10.
Kanitz A, Imig J, Dziunycz PJ, Primorac A, Galgano A, Hofbauer GF, et al. The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma. PLoS ONE. 2012;7, e49568.CrossRefPubMedPubMedCentral
11.
Wang A, Landen NX, Meisgen F, Lohcharoenkal W, Stahle M, Sonkoly E, et al. MicroRNA-31 is overexpressed in cutaneous squamous cell carcinoma and regulates cell motility and colony formation ability of tumor cells. PLoS ONE. 2014;9, e103206.CrossRefPubMedPubMedCentral
12.
Hameetman L, Commandeur S, Bavinck JN, Wisgerhof HC, de Gruijl FR, Willemze R, et al. Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients. BMC Cancer. 2013;13:58.CrossRefPubMedPubMedCentral
13.
Yu X, Li Z. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis (review). Int J Mol Med. 2014;34:923–33.PubMed
14.
Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer. 2015;18:43–54.CrossRefPubMed
15.
16.
Liu G, Liu R, Li Q, Tang X, Yu M, Li X, et al. Identification of microRNAs in wool follicles during anagen, catagen, and telogen phases in Tibetan sheep. PLoS ONE. 2013;8, e77801.CrossRefPubMedPubMedCentral
17.
Li Z, Yu X, Shen J, Chan MT, Wu WK. MicroRNA in intervertebral disc degeneration. Cell Prolif. 2015;48(3):278–83.CrossRefPubMed
18.
Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J, et al. By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth. Oncotarget. 2014;6(19):17559–69.CrossRef
19.
Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt pathway by targeting HOXD10 in intervertebral disc degeneration. PLoS ONE. 2013;8, e83080.CrossRefPubMedPubMedCentral
20.
Rao SA, Arimappamagan A, Pandey P, Santosh V, Hegde AS, Chandramouli BA, et al. miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. PLoS ONE. 2013;8, e63164.CrossRefPubMedPubMedCentral
21.
Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS ONE. 2012;7, e35661.CrossRefPubMedPubMedCentral
22.
Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo X, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS ONE. 2012;7, e41629.CrossRefPubMedPubMedCentral
23.
Jung CJ, Iyengar S, Blahnik KR, Ajuha TP, Jiang JX, Farnham PJ, et al. Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation. PLoS ONE. 2011;6, e27740.CrossRefPubMedPubMedCentral
24.
Vrba L, Munoz-Rodriguez JL, Stampfer MR, Futscher BW. Mirna gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PLoS ONE. 2013;8, e54398.CrossRefPubMedPubMedCentral
25.
Denoyelle C, Lambert B, Meryet-Figuiere M, Vigneron N, Brotin E, Lecerf C, et al. miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation. Cell Death Dis. 2014;5, e1445.CrossRefPubMedPubMedCentral
26.
Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ, et al. Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J. 2010;24:3427–37.CrossRefPubMedPubMedCentral
27.
Worley LA, Long MD, Onken MD, Harbour JW. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res. 2008;18:184–90.CrossRefPubMed
28.
29.
Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical implications in Ewing’s sarcoma. Cell Prolif. 2015;48:1–6.CrossRefPubMed
30.
Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG, et al. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res. 2008;68:1362–8.CrossRefPubMed
31.
Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, Taioli E. MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis. 2010;31:864–70.CrossRefPubMedPubMedCentral
32.
Alsaleh G, Suffert G, Semaan N, Juncker T, Frenzel L, Gottenberg JE, et al. Bruton’s tyrosine kinase is involved in miR-346-related regulation of IL-18 release by lipopolysaccharide-activated rheumatoid fibroblast-like synoviocytes. J Immunol. 2009;182:5088–97.CrossRefPubMed
33.
Chen Y, Du J, Zhang Z, Liu T, Shi Y, Ge X, et al. MicroRNA-346 mediates tumor necrosis factor alpha-induced downregulation of gut epithelial vitamin d receptor in inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20:1910–8.CrossRefPubMedPubMedCentral
34.
Chen J, Tian J, Tang X, Rui K, Ma J, Mao C, et al. MiR-346 regulates CD4+CXCR5+ T cells in the pathogenesis of Graves’ disease. Endocrine. 2015;49(3):752–60.CrossRefPubMed
35.
Semaan N, Frenzel L, Alsaleh G, Suffert G, Gottenberg JE, Sibilia J, et al. miR-346 controls release of TNF-alpha protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilization. PLoS ONE. 2011;6, e19827.CrossRefPubMedPubMedCentral
36.
Xiao J, Liu D, Jiao W, Guo J, Wang X, Zhang X, et al. Effects of microRNA-346 on epithelial-mesenchymal transition in mouse podocytes. Gene. 2015;560:195–9.CrossRefPubMed
37.
Cabodi S, del Pilar C-LM, Di Stefano P, Defilippi P. Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer. 2010;10:858–70.CrossRefPubMed
38.
Repetto D, Aramu S, Boeri Erba E, Sharma N, Grasso S, Russo I, et al. Mapping of p140Cap phosphorylation sites: the EPLYA and EGLYA motifs have a key role in tyrosine phosphorylation and Csk binding, and are substrates of the Abl kinase. PLoS ONE. 2013;8, e54931.CrossRefPubMedPubMedCentral
39.
Yamauchi M, Sudo K, Ito H, Iwamoto I, Morishita R, Murai T, et al. Localization of multidomain adaptor proteins, p140Cap and vinexin, in the pancreatic islet of a spontaneous diabetes mellitus model, Otsuka Long-Evans Tokushima fatty rats. Med Mol Morphol. 2013;46:41–8.CrossRefPubMed
40.
Sharma N, Repetto D, Aramu S, Grasso S, Russo I, Fiorentino A, et al. Identification of two regions in the p140Cap adaptor protein that retain the ability to suppress tumor cell properties. Am J Cancer Res. 2013;3:290–301.PubMedPubMedCentral
41.
Di Stefano P, Damiano L, Cabodi S, Aramu S, Tordella L, Praduroux A, et al. p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. EMBO J. 2007;26:2843–55.CrossRefPubMedPubMedCentral
42.
Cao M, Hou D, Liang H, Gong F, Wang Y, Yan X, et al. miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1. Eur J Cancer. 2014;50(5):1013–24.CrossRefPubMed
43.
Xu X, Wang W, Su N, Zhu X, Yao J, Gao W, et al. miR-374a promotes cell proliferation, migration and invasion by targeting SRCIN1 in gastric cancer. FEBS Lett. 2015;589:407–13.CrossRefPubMed
Metadata
Title
MicroRNA-346 functions as an oncogene in cutaneous squamous cell carcinoma
Authors
Bin Chen
Wenyan Pan
Xiaoxi Lin
Zhenzhen Hu
Yunbo Jin
Hui Chen
Gang Ma
Yajing Qiu
Lei Chang
Chen Hua
Yun Zou
Yang Gao
Hanru Ying
Dongze Lv
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4046-2

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Original Article

Gambogic acid enhances the radiosensitivity of human esophageal cancer cells by inducing reactive oxygen species via targeting Akt/mTOR pathway

Erratum

Erratum to: The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells

Original Article

Identification of expression quantitative trait loci of RPTOR for susceptibility to glioma

Original Article

SNHG3 correlates with malignant status and poor prognosis in hepatocellular carcinoma

Original Article

A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma

OriginalPaper

Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits